Recent diagnostic modalities for bladder cancer.
Recent advances in hybridoma technology, immunohistochemistry, cytopathology, cytogenetics, and molecular biology have not only furthered our understanding of the biology of bladder cancer but are also beginning to find clinical applications in the early diagnosis of the disease. It is likely that further study and refinement of these tools could reliably identify patients with superficial bladder tumors who are at increased risk for subsequent muscle infiltrative disease, or patients whose tumors are not amenable to current front-line chemotherapy.
Sheinfeld
J
J
Memorial Sloan-Kettering Cancer Center, New York, New York.
Cordon-Cardo
C
C
Bander
N H
NH
D000951:Antigens, Neoplasm / Q000032:analysis / Q000235:genetics; D014408:Biomarkers, Tumor / Q000032:analysis*; D001789:Blood Group Antigens / Q000235:genetics; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis / Q000235:genetics / Q000276:immunology; D002869:Chromosome Aberrations; D005964:Glucosyltransferases / Q000235:genetics; D006133:Growth Substances / Q000235:genetics; D006801:Humans; D009363:Neoplasm Proteins / Q000032:analysis / Q000235:genetics; D009857:Oncogenes; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000276:immunology
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D001789:Blood Group Antigens; D006133:Growth Substances; D009363:Neoplasm Proteins; D005964:Glucosyltransferases